{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T23:14:44Z","timestamp":1789600484243,"version":"build-2803163510"},"reference-count":27,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T00:00:00Z","timestamp":1748304000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Finerenone has been shown to improve outcomes in patients with heart failure (HF), encompassing those with reduced (HFrEF), mildly reduced (HFmrEF), or preserved ejection fraction (HFpEF). However, its clinical use is accompanied by notable adverse effects. This study aimed to evaluate the relative risks of adverse events associated with finerenone across HF phenotypes.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A systematic search of PubMed, Embase, and Web of Science identified six randomized controlled trials involving 8,527 HF patients. The analysis considered hyperkalemia, hypotension, treatment-emergent adverse events (TEAEs), treatment-emergent serious adverse events (TESAEs), and treatment discontinuation due to adverse events.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Finerenone significantly increased the risk of hyperkalemia (RR\u2009=\u20092.07, 95% CI 1.77-2.44, <jats:italic>P<\/jats:italic> &amp;lt; 0.00001) and hypotension (RR\u2009=\u20091.49, 95% CI 1.31-1.68, <jats:italic>P<\/jats:italic> &amp;lt; 0.00001) compared to placebo, irrespective of HF phenotype. No significant differences were observed between finerenone and placebo in terms of TEAEs, TESAEs, or treatment discontinuation when analyzing the overall heart failure population. Compared to eplerenone, finerenone was associated with a lower risk of TEAEs (RR\u2009=\u20090.93, 95% CI: 0.89-0.98) and TESAEs (RR\u2009=\u20090.74, 95% CI: 0.66-0.84), with similar discontinuation rates. Additionally, one included study suggested that finerenone may have a lower risk of TEAEs (RR\u2009=\u20090.64, 95% CI 0.56-0.74), treatment discontinuation (RR\u2009=\u20090.37, 95% CI 0.25-0.54) and hyperkalemia (RR\u2009=\u20090.41, 95% CI 0.21-0.79) compared to spironolactone, with similar rates of hypotension (RR\u2009=\u20090.61, 95% CI 0.29-1.30) in HFrEF.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Finerenone (10-25 mg) showed a similar safety profile to placebo, with no significant differences in TEAEs, TESAEs, or treatment discontinuation. Compared to eplerenone, finerenone was associated with fewer TEAEs and TESAEs, with comparable discontinuation rates. Moreover, in patients with HFrEF, finerenone may offer lower risks of TEAEs, treatment discontinuation, and hyperkalemia than spironolactone, with similar rates of hypotension.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fcvm.2025.1601552","type":"journal-article","created":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T01:23:05Z","timestamp":1748308985000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Adverse effects of finerenone in patients with heart failure: a systematic review and meta-analysis"],"prefix":"10.3389","volume":"12","author":[{"given":"Wanqian","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingan","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangtao","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinghua","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pingping","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,5,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1038\/s41569-024-01046-6","article-title":"Global epidemiology of heart failure","volume":"21","author":"Khan","year":"2024","journal-title":"Nat Rev Cardiol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"897423","DOI":"10.3389\/fcvm.2022.897423","article-title":"Efficacy and safety of sacubitril\/valsartan on heart failure with preserved ejection fraction: a meta-analysis of randomized controlled trials","volume":"9","author":"Yu","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"B3","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/s10741-023-10363-w","article-title":"Adverse effects of sodium-glucose cotransporter-2 inhibitors in patients with heart failure: a systematic review and meta-analysis","volume":"29","author":"Pozzi","year":"2024","journal-title":"Heart Fail Rev"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1056\/NEJMoa2407107","article-title":"Finerenone in heart failure with mildly reduced or preserved ejection fraction","volume":"391","author":"Solomon","year":"2024","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.1093\/eurheartj\/eht187","article-title":"Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial","volume":"34","author":"Pitt","year":"2013","journal-title":"Eur Heart J"},{"key":"B6","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular events with finerenone in kidney disease and type 2 diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"N Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1002\/ejhf.2469","article-title":"Finerenone in patients with chronic kidney disease and type 2 diabetes with and without heart failure: a prespecified subgroup analysis of the FIDELIO-DKD trial","volume":"24","author":"Filippatos","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"B9","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1161\/CIRCULATIONAHA.121.057983","article-title":"Finerenone reduces risk of incident heart failure in patients with chronic kidney disease and type 2 diabetes: analyses from the FIGARO-DKDTrial","volume":"145","author":"Filippatos","year":"2022","journal-title":"Circulation"},{"key":"B10","doi-asserted-by":"publisher","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1253\/circj.CJ-16-0122","article-title":"A randomized controlled study of finerenone vs. Eplerenone in Japanese patients with worsening chronic heart failure and diabetes and\/or chronic kidney disease","volume":"80","author":"Sato","year":"2016","journal-title":"Circ J"},{"key":"B12","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1093\/eurheartj\/ehw132","article-title":"A randomized controlled study of finerenone vs. Eplerenone in patients with worsening chronic heart failure and diabetes mellitus and\/or chronic kidney disease","volume":"37","author":"Filippatos","year":"2016","journal-title":"Eur Heart J"},{"key":"B13","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1161\/CIRCULATIONAHA.124.072011","article-title":"Efficacy and safety of finerenone across the ejection fraction spectrum in heart failure with mildly reduced and preserved ejection fraction: a prespecified analysis of the FINEARTS-HF trial","volume":"151","author":"Docherty","year":"2025","journal-title":"Circulation"},{"key":"B14","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1097\/FJC.0000000000000091","article-title":"Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury","volume":"64","author":"Kolkhof","year":"2014","journal-title":"J Cardiovasc Pharmacol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.mce.2011.06.025","article-title":"Molecular pharmacology of the mineralocorticoid receptor: prospects for novel therapeutics","volume":"350","author":"Kolkhof","year":"2012","journal-title":"Mol Cell Endocrinol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1093\/ehjcvp\/pvw016","article-title":"Mineralocorticoid receptor antagonists in patients with heart failure: current experience and future perspectives","volume":"3","author":"Pitt","year":"2017","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","article-title":"Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction","volume":"381","author":"Solomon","year":"2019","journal-title":"N Engl J Med"},{"key":"B18","doi-asserted-by":"publisher","first-page":"e70062","DOI":"10.14814\/phy2.70062","article-title":"Role of L-type Ca2+-channels in the vasorelaxing response to finerenone in arteries of human visceral adipose tissue","volume":"12","author":"Schinzari","year":"2024","journal-title":"Physiol Rep"},{"key":"B19","doi-asserted-by":"publisher","first-page":"678614","DOI":"10.3389\/fcvm.2021.678614","article-title":"Similarities and differences between HFmrEF and HFpEF","volume":"8","author":"Li","year":"2021","journal-title":"Front Cardiovasc Med"},{"key":"B20","doi-asserted-by":"publisher","first-page":"928232","DOI":"10.3389\/fphys.2022.928232","article-title":"Current understanding of molecular pathophysiology of heart failure with preserved ejection fraction","volume":"13","author":"Budde","year":"2022","journal-title":"Front Physiol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/s10157-023-02413-2","article-title":"The role of a novel mineralocorticoid receptor antagonist, finerenone, in chronic kidney disease: mechanisms and clinical advances","volume":"28","author":"Chen","year":"2024","journal-title":"Clin Exp Nephrol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1177\/2047487319870344","article-title":"Oxidative stress and inflammation in the evolution of heart failure: from pathophysiology to therapeutic strategies","volume":"27","author":"Aimo","year":"2020","journal-title":"Eur J Prev Cardiol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1002\/ejhf.3618","article-title":"Clinical management and therapeutic optimization of patients with heart failure with reduced ejection fraction and low blood pressure. A clinical consensus statement of the heart failure association (HFA) of the ESC","volume":"27","author":"Skouri","year":"2025","journal-title":"Eur J Heart Fail"},{"key":"B24","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1007\/s10741-019-09790-5","article-title":"Comparative efficacy and safety of mineralocorticoid receptor antagonists in heart failure: a network meta-analysis of randomized controlled trials","volume":"24","author":"Yang","year":"2019","journal-title":"Heart Fail Rev"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1002\/cmdc.201200081","article-title":"Discovery of BAY 94-8862: a nonsteroidal antagonist of the mineralocorticoid receptor for the treatment of cardiorenal diseases","volume":"7","author":"B\u00e4rfacker","year":"2012","journal-title":"ChemMedChem"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1517\/13543784.2015.1059819","article-title":"Finerenone: third-generation mineralocorticoid receptor antagonist for the treatment of heart failure and diabetic kidney disease","volume":"24","author":"Liu","year":"2015","journal-title":"Expert Opin Investig Drugs"},{"key":"B27","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/s40119-022-00269-3","article-title":"Cardiovascular and renal outcomes with finerenone, a selective mineralocorticoid receptor antagonist","volume":"11","author":"Palanisamy","year":"2022","journal-title":"Cardiol Ther"}],"updated-by":[{"DOI":"10.3389\/fcvm.2025.1652440","type":"corrigendum","label":"Corrigendum","source":"publisher","updated":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T00:00:00Z","timestamp":1753401600000}}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2025.1601552\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T14:06:35Z","timestamp":1753452395000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2025.1601552\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,27]]},"references-count":27,"alternative-id":["10.3389\/fcvm.2025.1601552"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2025.1601552","relation":{"corrigendum":[{"id-type":"doi","id":"10.3389\/fcvm.2025.1652440","asserted-by":"object"}]},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,27]]},"article-number":"1601552"}}